Relief for migraine pain

Nursing, Apr 2003

RELPAX

Pfizer has received FDA approval for Relpax (eletriptan hydrobromide) tablets, indicated to relieve pain and other symptoms of a migraine attack. A selective 5-hydroxytryptamine 1B1D (5-HTIB/ID) receptor agonist, Relpax acts at serotonin 5-HTIB receptors on intracranial blood vessels and at 5HT1D receptors on sensory nerve endings. In clinical trials involving over 9,000 patients, Relpax relieved migraine pain and other symptoms such as nausea and sensitivity to light and sound.

Relpax is available in 20-mg and 40-mg doses; the maximum recommended single dose is 40 mg.

The most common adverse reactions reported in clinical trials included fatigue, somnolence, nausea, and dizziness. Relpax is contraindicated in patients with severe hepatic impairment and in those older than 65 or younger than 18. It shouldn't be used concurrently (within 72 hours) with a potent CYP3A4 inhibitor, such as ketoconazole (Nizoral), fluoxetine (Prozac), and sertraline (Zoloft).